Tissue Regenix has widened its H1 pretax loss to £5.4m, from a year-earlier loss of £4.0m. Revenue was just £631,000, from £252,000. Most of the losses were administrative expenses.
"The next twelve months promise some significant milestones for Tissue Regenix, including the launch of our first orthopaedic application in Europe, the launch of our second wound care product, SurgiPure XD into the US and the ongoing regulatory submissions to the German authorities for decellurised tissues to be treated at GBM-V," the company said.
"Alongside this, the continued growth of DermaPure, as evidenced by these results, and the ongoing development of our orthopaedic business within the US ensure that we remain on track to end our year accomplishing our corporate goals, and we look forward to reporting our progress over the coming months."